{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T12:53:52Z","timestamp":1790254432146,"version":"4.1.0"},"reference-count":23,"publisher":"Informa UK Limited","issue":"5","content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Review of Pharmacoeconomics & Outcomes Research"],"published-print":{"date-parts":[[2019,9,3]]},"DOI":"10.1080\/14737167.2019.1651646","type":"journal-article","created":{"date-parts":[[2019,8,19]],"date-time":"2019-08-19T03:24:45Z","timestamp":1566185085000},"page":"529-536","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":26,"title":["Is it a Chimera? A systematic review of the economic evaluations of CAR-T cell therapy"],"prefix":"10.1080","volume":"19","author":[{"given":"Panagiotis","family":"Petrou","sequence":"first","affiliation":[{"name":"School of Sciences and Engineering, Pharmacy School, Pharmacoepidemiology-Pharmacovigilance, University of Nicosia, Nicosia, Cyprus"},{"name":"Health Insurance Organisation, Nicosia, Cyprus"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2019,8,19]]},"reference":[{"key":"CIT0001","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1709866"},{"key":"CIT0002","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1707447"},{"key":"CIT0003","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2009.06.005"},{"key":"CIT0004","doi-asserted-by":"publisher","DOI":"10.1080\/13696998.2018.1529674"},{"key":"CIT0005","volume-title":"44th Annual Meeting of the European Society for Blood and Marrow Transplantation, Lisbon, Portugal.\u00a02018","author":"Lin VW"},{"key":"CIT0006","doi-asserted-by":"publisher","DOI":"10.1001\/jamapediatrics.2018.2530"},{"key":"CIT0007","unstructured":"US Food and Drug Administration. Tisagenlecleucel (CTL019) for the treatment of pediatric and young adult patients with relapsed\/refractory b-bell acute lymphoblastic leukemia. FDA Advisory Committee Briefing Document.Washington, DC: US Food and Drug Administration; 2017."},{"key":"CIT0008","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.03.8554"},{"issue":"32","key":"CIT0009","doi-asserted-by":"crossref","first-page":"3192","DOI":"10.1200\/JCO.2018.79.0642","volume":"36","author":"Lin JK","year":"2018","journal-title":"J Clin Oncol"},{"key":"CIT0010","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djy193"},{"key":"CIT0011","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-08-374710"},{"key":"CIT0012","doi-asserted-by":"crossref","unstructured":"Yang H, Qi C, Zhang J, et al. Cost-effectiveness of tisagenlecleucel for adults with relapsed or refractory diffuse large b-cell lymphoma: a canadian societal perspective. Barcelona, Spain; 2018 Nov.","DOI":"10.1016\/j.jval.2018.09.260"},{"key":"CIT0013","doi-asserted-by":"crossref","unstructured":"Yang H, Zhang J, Hampe M. Cost-effectiveness of tisagenlecleucel in pediatric and young adult patients with relapsed or refractory b-cell acute lymphoblastic leukemia: a canadian societal perspective. Barcelona, Spain; 2018 Nov. Code: PCN170 ISPOR Europe 2018","DOI":"10.1016\/j.jval.2018.09.253"},{"key":"CIT0014","doi-asserted-by":"crossref","first-page":"4779","DOI":"10.1182\/blood-2018-99-113838","volume":"132","author":"Marchetti M","year":"2018","journal-title":"Blood"},{"issue":"11","key":"CIT0015","volume":"20","author":"Bae YHJ","year":"2014","journal-title":"J Manag Care Spec Pharm"},{"key":"CIT0016","doi-asserted-by":"crossref","unstructured":"Hollmann S, Painter C, Hogan A et al. Budget impact analysis of tisagenlecleucel for the treatment of paediatric and young adult patients with relapsed or refractory b-cell acute lymphoblastic leukaemia in England. Barcelona Spain; 2018 Nov. Code: PCN68 ISPOR Europe 2018.","DOI":"10.1016\/j.jval.2018.09.150"},{"key":"CIT0017","unstructured":"Car T-cell therapies in France PPRI Webinar \u2013 13 February. Jonathan Rodrigues assessed in February 2019."},{"key":"CIT0018","unstructured":"NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE. Final appraisal document Tisagenlecleucel for treating relapsed or refractory B-cell acute lymphoblastic leukaemia in people aged up to 25 years. [cited 2019 May]. Available from: https:\/\/www.nice.org.uk\/guidance\/ta554\/documents\/final-appraisal-determination-document"},{"key":"CIT0019","volume":"6","author":"Kefalas P","year":"2018","journal-title":"J Mark Access Health Policy"},{"key":"CIT0020","unstructured":"Entela Xoxi Agenda item 4. Real world evidence data collection Italian Experience on Registries Commission expert group on \u201cSafe and Timely Access to Medicines for Patients\u201d(STAMP) Brussels. 2016 Mar 10."},{"key":"CIT0021","doi-asserted-by":"publisher","DOI":"10.1080\/13696998.2018.1499520"},{"key":"CIT0022","doi-asserted-by":"publisher","DOI":"10.1016\/j.drudis.2018.02.012"},{"issue":"1","key":"CIT0023","volume":"9","author":"Ofman E","year":"2003","journal-title":"J Manag Care Pharm"}],"container-title":["Expert Review of Pharmacoeconomics & Outcomes Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/14737167.2019.1651646","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,8,14]],"date-time":"2020-08-14T22:15:52Z","timestamp":1597443352000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/14737167.2019.1651646"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8,19]]},"references-count":23,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2019,9,3]]}},"alternative-id":["10.1080\/14737167.2019.1651646"],"URL":"https:\/\/doi.org\/10.1080\/14737167.2019.1651646","relation":{},"ISSN":["1473-7167","1744-8379"],"issn-type":[{"value":"1473-7167","type":"print"},{"value":"1744-8379","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,8,19]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ierp20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ierp20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2019-05-02","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-07-31","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-08-19","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}